Characterization of hereditary angioedema population in Argentina: A nationwide studyਮ Authors: Darío Josviak, Daniel Vázquez, Pablo Martínez, Iris Medina, Ricardo Zwiener, Alejandro Berardi, Gonzalo Chorzepa, Carina Luna, Vanessa Pussetto, Natalia Fili, Mónica Marocco, Gabriel Fueyo, Martina Indiveri, Florencia Baillieau, René Baillieau, Adriana Brandi, Marcela García, Gustavo Vijoditz, Matías Oleastro, Claudio Parisi, Marcela Chinigo, Andrea Gómez Raccio, Andrea Mariño, Patricia Ronco, Alejandra Schmid, Claudio Cambiasso, Daiana Espantoso, Miguel Galicchio, Cora Onetti, Adrián Kahn, Claudio Fantini, HAE Scientific Committee of Published: 2026 ABSTRACT AbstractBackgroundData about hereditary angioedema (HAE) from Latin American countries are lacking. Our main objective was to characterize the epidemiology, clinical presentation, and treatment patterns of HAE patients from Argentina at a nationwide level.MethodsA non-interventional, observational, web-based survey was conducted, aimed at physicians treating patients with a confirmed diagnosis of HAE. Data about demographic characteristics, HAE type and family history, clinical pattern, attack frequency and triggers, treatment patterns, and use of validated HAE scores were collected to develop a patient registry.ResultsData from 538 patients submitted by 75 physicians were obtained. Median age was 33 years (IQR:20–46). Most patients were female (58.73%). Median age at presentation of first symptoms was 12 years (IQR:5–18). Median time from presentation to a confirmed diagnosis of HAE was 10 years (IQR:5–18). Most patients had deficiency of C1–INH (HAE-1, 76%). Variants in the F12 gene (HAE-FXII) were found in 7% of subjects; variants in DAB2IP (p.D239 N) (HAE-DAB2IP) were identified in 7 subjects. Severity of HAE was predominantly moderate (37%). Most reported triggers were emotional stress (75.55%) and physical trauma (69.59%). Specific treatment for attacks was prescribed for 88% of patients. Icatibant was the most prescribed drug (76.91%). Long-term prophylaxis (LTP) was used in 28.34% of subjects, with lanadelumab being the most prescribed agent (58.45%).ConclusionArgentine HAE patients share several characteristics with patients from real-world studies, but some findings (time to diagnosis, low LTP rates, relatively high rates of HAE-FXII and a novel, recently characterized form of HAE-DAB2IP) require further research.Keywords: Angioedemas, Hereditary, Argentina, Pragmatic trials Introduction Hereditary angioedema (HAE) is a rare and potentially life-threatening disease, characterized by recurrent episodes of swelling that primarily affect the skin and mucous membranes. These episodes may be life-threatening, particularly when the upper airways are involved. The central pathophysiological mechanism of HAE lies in the excessive production of bradykinin, a vasoactive peptide that increases vascular permeability, leading to the development of edema. In most cases, this bradykinin overproduction is due to a quantitative or functional deficiency of C1 inhibitor (C1–INH), a key regulatory protein of the complement system. The diagnosis of HAE is based on the determination of C1–INH concentration and functional activity; measurement of plasma C4 levels may also be useful as they are usually low during episodes of angioedema.1 In recent years, significant advances have been made in the understanding of HAE pathophysiology, highlighting the growing importance of genetic testing, particularly in patients with normal C1–INH levels, which has enabled the identification of new variants and subtypes of the disease.2 Despite these advances, the management of HAE continues to face significant challenges. These include diagnostic delays, which may result in serious complications and the limited availability of effective therapies or access to them in some countries, hindering adequate disease control. The Asociación Argentina de Alergia e Inmunología Clínica (AAAeIC), a member of the World Allergy Organization, is the leading professional association of allergists in our country and brings together more than 500 specialists. Within the association, the Scientific Committee on HAE operates, composed of physicians committed to the awareness, diagnosis and treatment of this disease, and addressing patient-related issues. In 2021, this group published a National Consensus on the diagnosis and treatment of HAE,3 which will be updated shortly due to the need to incorporate new therapies that have recently become available in our country, particularly for long-term prophylaxis (LTP), one of the areas requiring greater emphasis. This need was also demonstrated by our working group in a quality-of-life study involving 100 Argentine patients, published in 2023.4 The present study investigates the current epidemiology of the disease, the way healthcare professionals manage these patients, and the unmet needs in this field, thereby laying the groundwork for updating the aforementioned consensus. At the same time, we acknowledge a significant lack of epidemiological and clinical data from Latin American countries, which limits the global understanding of the impact of HAE in this region. The primary objective of the study presented herein is to characterize the epidemiology, clinical presentation, and treatment patterns of patients with HAE in Argentina, thus providing relevant national-level information that may help improve diagnosis, management, and quality of life in patients affected by this condition. Methods Survey design A non-interventional, observational, nationwide, web-based survey was conducted, aimed at physicians treating patients with a diagnosis of HAE confirmed by a specialized laboratory following national consensus guidelines3 and accepted international World Allergy Organization / European Academy of Allergy and Clinical Immunology (WAO/EAACI) guidelines.5 A structured questionnaire was developed ad hoc and physicians were contacted by e-mail on behalf of the Scientific Committee of AAAeIC to participate. A Google form (GForm) was designed and a unique case report form was completed for each individual patient. Data collection was anonymized to preserve patient confidentiality. Potential duplicate records were checked before data analysis. Data about demographic characteristics, HAE type (according to Maurer et al)5 and severity (according to Prior et al),6 family history of HAE, clinical pattern, comorbidities, attack frequency and triggers, treatment patterns (prophylaxis and attacks), medical insurance, and use of validated HAE scores were collected to develop a patient registry. No patient age limits were considered for inclusion. Patients without a confirmed laboratory diagnosis of HAE, not residing in Argentina, or deceased were excluded from the data collection. Several datasets were reserved for further research, including the pediatric population subgroup. Ethical issues The study was conducted in accordance with the last version of the Declaration of Helsinki and Good Clinical Practice guidelines. The protocol was reviewed and approved by the Institutional Research Ethics Committee Vitae. Since it was an observational, retrospective, non-interventional study based on anonymized data obtained from medical records, no informed consent from individual patients was required. Statistical analysis All data were retrieved from July 12 to December 9, 2024 and tabulated in spreadsheets. Continuous variables were expressed as mean ± standard deviation for normally distributed variables according to the Shapiro–Wilk test. Non-normally distributed variables are expressed as the median value with interquartile range (IQR). Categorical variables are presented as frequencies and percentages. Differences between groups were determined using the chi squared test for categorical variables. Differences in continuous variables were analyzed using the unpaired t-test or the Mann–Whitney U test, as appropriate. Missing data were excluded from the analyses. A p-value <0.05 was considered statistically significant. Statistical analyses were performed using SPSS 20.0.0 (IBM Corporation). Results Demographic data Data from 538 patients submitted by 75 physicians with a confirmed diagnosis of HAE were obtained. Median age was 33 years (IQR: 20–46), with 22.12% of pediatric subjects (aged under 18). Most patients were female (58.73%). Main demographic data are summarized in Table 1. Table 1Main demographic data.Table 1Full set, n538Female, n/N (%)316/538 (58.73%)Age, median (IQR)33 years (20–46)Age distribution Pediatric patients (age <18), n/N (%)119/538 (22.12%) Adults (age 18–65), n/N379/538 (70.45%) Elderly (age >65), n/N40/538 (7.43%)Ethnic distribution (a) White, hispanic, n/N (%)444/505 (87.92%) Mestizo, n/N (%)29/505 (5.74%) White, not hispanic, n/N (%)26/505 (5.15%) Other, n/N (%)6/505 (1.19%)Literacy (b) Primary school (complete or incomplete), n/N (%)114/488 (23.36%) Secondary school (complete or incomplete), n/N (%)242/488 (49.59%) Higher education (complete or incomplete), n/N (%)132/488 (27.05%)aData available for 505 subjects.bData available for 488 subjects Main demographic data. Data available for 505 subjects. Data available for 488 subjects Median age at presentation of first symptoms was 12 years (IQR: 5–18), while median age at diagnosis was 22 years (IQR: 10–36). Median time from presentation to a confirmed diagnosis of HAE was 10 years (IQR: 5–18) (Fig. 1). Half of the patients with available data underwent control visits every 3 months. Most patients (88%) had at least 1 relative with a confirmed diagnosis of HAE, including parents, siblings, or second-degree relatives. The number of affected relatives is summarized in Table 2. Time from the first symptom to the confirmed diagnosis of HAE. Table 2Proportion of patients with at least 1 relative with confirmed diagnosis of HAE.Table 2Affected relativesn/N (%) (a)1 relative70/427 (16.4%)2 relatives75/427 (17.6%)3 relatives58/427 (13.6%)4 relatives50/427 (11.7%)5 relatives24/427 (5.6%)≥6 relatives150/427 (35.1%)aData available for 427 patients Proportion of patients with at least 1 relative with confirmed diagnosis of HAE. Data available for 427 patients HAE-related data Most patients had quantitative deficiency of C1–INH (HAE-1, 76%), with 15% having dysfunctional C1–INH (HAE-2) and 9% having normal C1–INH level and function (HAE-nC1-INH) (Fig. 2A). At least 1 comorbidity was reported in 35% of patients. Most prevalent comorbidities included hypertension (10.1%), mental health disorders (mainly anxiety and depression, 10.1%), dyslipidemia (8.1%), diabetes mellitus (8.1%), rheumatic disorders (8.1%), and obesity (7.1%). Variants in the F12 gene (HAE-FXII) were found in 7% of subjects (n = 35) and variants in DAB2IP (p.D239 N) (HAE-DAB2IP) were identified in 7 subjects. [A] Patient distribution according to HAE type. [B] Patient distribution according to HAE severity (n = 513 with available data). Severity of HAE was predominantly moderate (37%), while 11% of our patients were asymptomatic (Fig. 2B). More than half of the study population was free of weekly attacks (55.2%). At least 1 attack per month was reported by 61% of patients, and 80% experienced at least 1 attack per year. Detailed information is summarized in Fig. 3. Triggers for HAE attacks were identified in 62% of patients. Most reported triggers were emotional stress (75.55%), physical trauma (69.59%), menstruation (28.58% of females), infections (21.63%), non-traumatic compression (15.99%), pregnancy (13.09% of females), estrogen-based therapies (12.04% of females), long-standing position (7.21%), food (6.58%), and estrogen-free drugs (mainly nonsteroidal anti-inflammatory drugs [n = 5] and enalapril). Frequency of HAE attacks. [A] Weekly frequency (n = 498). [B] Monthly frequency (n = 499). [C] Yearly frequency (n = 500). Percentages may add up to more than 100% because some patients have variable attack frequency. Treatment patterns In Argentina, at the time the study was conducted, the following medications were available: for the treatment of attacks, intravenous C1–INH concentrate and icatibant; for short-term prophylaxis, intravenous C1–INH concentrate; and for LTP, lanadelumab, berotralstat, subcutaneous C1–INH concentrate, attenuated androgens, and tranexamic acid. All patients are treated according to the Argentine Consensus on HAE.3 However, not all of them have access to the same quality of treatment. This is due to the complexity of the Argentine healthcare system, which comprises 3 main levels of coverage: the public healthcare system, the private healthcare system, and union-based health insurance schemes. Depending on the type of coverage, patient's access to medication varies and is not always equitable. Specific treatment for HAE attacks was prescribed for 88% of patients. Icatibant was the most prescribed drug (76.91%), self-administered on demand at the patient's home, followed by plasma-derived C1–INH (34.2%), requiring care at a medical site (Fig. 4A). LTP was used in 28.34% of subjects, with lanadelumab being the most prescribed agent (58.45%) (Fig. 4B). Patients receiving LTP were predominantly female (64.08%), significantly older than participants not receiving LTP (42 years [IQR: 31–56] vs. 30 years [IQR: 15–46]; p < 0.01). Treatment patterns of HAE attacks (panel A, n = 473) and long-term prophylaxis (panel B, n = 152). Percentages may add up to more than 100% as some patients use more than 1 drug. Discussion In our nationwide study, the HAE population was young and generally presented moderately severe disease. A high prevalence of patients had identifiable triggers and access to specific treatment for attacks; nevertheless, less than 30% of them were receiving LTP. HAE is an infrequent, but potentially fatal disease, which is often underdiagnosed and undertreated. Data from Latin America are scarce and usually limited to case series.7,8 To the best of our knowledge, our study describes one of the largest real-world cohort of HAE patients in the region. The estimated HAE prevalence in the general population is 1 in 50,000 individuals;4 the total Argentine population is 45 million;9 as a consequence, there should be approximately 900 to 1000 patients in our country, of which our cohort represents a substantial proportion. This highlights the need for continued efforts in awareness and education among primary care physicians to increase diagnostic rates. In our study, median age was 33 years (IQR: 20–46), with 22.12% of subjects aged under 18. A female predominance was reported. Our results are similar to those from other real-world or mixed-methods epidemiologic approach studies in the Americas.10,11 The delay of a median 10 years from symptom onset to a definitive diagnosis resembles international data. A specific analysis of the pediatric and adolescent population is being performed for further publication. When an index case is diagnosed, the entire family is immediately evaluated, as 88% of our patients had ≥1 relative with confirmed HAE. However, given that 12% of the patients had no family history of HAE, a de novo variant could be potentially considered. HAE-1 was the most frequent type of HAE in our population, accounting for 76% of cases, slightly lower than the reported estimation in epidemiologic11 and review studies.12 It is worth noting that all patients suspected of HAE should be assessed for C1–INH function, C1–INH protein, and C4.5 Nevertheless, these tests are not always available in developing countries. C1–INH function test may be particularly challenging and might account for the lack of diagnosed patients with HAE-2 in resource-limited countries.13 When assessing the severity according to Prior et al,6 37% of patients were classified as having moderate HAE; no differences were found in the relative proportion of mild, moderate, or severe cases according to HAE type (data not shown). Seven percent of our cohort was diagnosed with HAE-FXII; these patients live in the Northeast provinces of Argentina in the border with Brazil. Both countries share an important German immigration in that region, which may explain this high prevalence of HAE-FXII.14 Of note, 7 patients were diagnosed with a novel missense variant (p.D239 N) in the DAB2IP gene (HAE-DAB2IP) that was identified in an Argentine family with HAE.15 The genetic diversity, including variants in non-classical genes like DAB2IP, suggests that further genomic exploration may reveal region-specific pathogenic mechanisms in South American populations. Even though most patients were free of weekly attacks, 61% and 80% of them reported at least 1 HAE attack per month or year, respectively. The clinical phenotype may vary significantly both among patients and within affected relatives, and is not correlated with C1–INH levels or function.16 In our cohort, at least 1 triggering factor has been identified in 62% of patients, a higher proportion than previously described.16 Emotional stress (75.55%) and physical trauma (69.59%) have been reported as the most frequent triggers, as described in previous research.16 The indications for treating HAE attacks have evolved over time; current international and national guidelines recommend immediate treating of attacks, regardless of location, to reduce its duration and severity.3,5,17 In our cohort, specific treatment for attacks was available in 88% of the population, with icatibant being the most prescribed drug, followed by plasma-derived C1–INH. Despite of broad access to attacks treatment, LTP was used only by 28.34% of subjects, who were significantly older than subjects non receiving prophylaxis. Of note, 68% of our population had moderate or severe HAE and would be considered as candidates for LTP. Although the frequency, severity, location of attacks, disease burden, subjective perception of the patients and the impact on quality of life are the key factors for initiating LTP,4,11,16 other aspects should be taken into account, specially treatment access in our country, disparities in health insurance, limited physicians awareness and regional heterogeneity in drugs availability. As a consequence, no homogeneous criteria for initiating LTP based on the frequency or severity of attacks can be defined.3 A shared decision between the specialized healthcare professional and the patient is advised and the need to optimize LTP access by the healthcare system is emphasized. Argentine guidelines of management of HAE highlights the importance of early referral of these patients to an experienced physician with the goal of reduce both treatment delay and healthcare costs.3 LTP, specially with monoclonal antibodies, has demonstrated significant benefits in reducing attack frequency and improving quality of life. These findings highlight the need for comprehensive national programs to ensure equitable access to both diagnostic tools and prophylactic therapies.5 In addition, more than 10.1% of our patients had at least a mental health disorder. Chronic unpredictability of attacks, risk of asphyxia and treatment limitations can lead to heightened anxiety and depressive symptoms. Moreover, metabolic conditions such as dyslipidemia and diabetes, observed in over 8% of patients, may reflect the broader cardiovascular risk profile or consequences of repeated corticosteroid exposure in patients treated prior to access to modern therapies. Our research has the inherent limitations of real-world studies, including the possibility of missing data (including potential information and/or recall bias), the lack of control over data quality, potential conscious and/or unconscious researcher bias, and the potential impact of unmeasured confounders. However, several strengths should be highlighted: First, our nationwide data are highly representative of the Argentine HAE population (538 retrieved patients of an estimated total of 900 subjects). Second, the data collection tool (GForm) is a validated and increasingly used instrument for biomedical research, which allows multiple users to collaborate on data collection. Third, data analysis was centrally performed. Fourth, the patient registry developed led to the inclusion of a large and diverse population, reflecting the real clinical practice. We conclude that Argentine HAE patients share several characteristics with patients from real-world studies, but some findings (low rates of LTP, a relatively high rate of HAE-FXII and a novel, recently characterized form of HAE-DAB2IP) require further research. Our results add new data to the growing body of evidence related to HAE in low- and medium-income countries. Author contributions Darío Josviack, Daniel Vázquez, Pablo Martínez, Iris Medina and Claudio Fantini participated in the conception and design of the study, the analysis and interpretation of data, drafting the article and developing the final version. All authors participated in the acquisition of data and revising the manuscript critically for important intellectual content. All authors approved the submitted version. Funding sources we have received an unrestrictive grant contributed equally by Bioprofarma Bagó, CSL Behring, Pint Pharma and Takeda for the development of our research. Ethics statement This study was conducted in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice guidelines. The protocol was reviewed and approved by the Institutional Research Ethics Committee Vitae, which granted a waiver of informed consent. Since it was an observational, retrospective, non-interventional study based on anonymized data obtained from medical records, no informed consent from individual patients was required under national regulations in Argentina. Declaration of generative AI and AI-assisted technologies in the writing process Nothing to disclose. Conflicts of interest Darío Josviack has received honoraria as speaker/advisor from CSL Behring, Pint Pharma and Takeda. Daniel Vázquez has received honoraria as speaker/advisor and grants for education and/or as an investigator from Biopharma Bagó, Casasco, CSL Behring, Elea, Europharma, GlaxoSmithKline, Novartis, Phoenix, Pint Pharma, Sanofi and Takeda. Pablo Martínez has received honoraria as speaker/advisor from Takeda. Ricardo Zwiener has received grants for hosting/travelling from Bagó, Pharvaris, Kalvista and Takeda; has received honoraria as speaker/advisor from AbbVie, Bagó, CSL Behring, Pharvaris, Kalvista, Sanofi and Takeda; has received honoraria as an investigator from Pharvaris and Sanofi. Alejandro Berardi has received honoraria as investigator from Sanofi, Chiesi and Pharvaris for finished or ongoing trials. Gonzalo Chorzepa has received honoraria as an advisor for Pint Pharma. Carina Luna has received honoraria as professor from the Universidad Nacional de Formosa; has received grants for hosting/travelling from Biopharma and Takeda. Natalia Fili has received grants for hosting/travelling from AbbVie, Bagó, Montpellier, Pharvaris, Pint Pharma, Siegfried, and Takeda; has received honoraria as an investigator from Pharvaris; and has received honoraria as speaker/advisor from CSL Behring, Pint Pharma and Takeda. Mónica Marocco has received honoraria as speaker/advisor for AbbVie, Bagó, Genzyme, Pint Pharma, Sanofi and Takeda. Martina Indiveri has received grants for hosting/travelling, education and assistance to Congresses from Byocrist and Takeda. René Baillieau has received grants for participation in Congresses from Pfizer and Takeda. Adriana Brandi has received grants for participation in Congresses from Pint Pharma and Takeda. Matías Oleastro has recieved honoraria as speaker from CSL Behring (Argentina and Chile) and Takeda (Argentina). Claudio Parisi has recieved honoraria as advisor from Nutricia and Takeda. Andrea Gómez Raccio has received honoraria as speaker/advisor from Takeda. Claudio Fantini has received grants for hosting/travelling from Bagó, CSL Behring, Sigfried and Takeda; has received honoraria as speaker/advisor from CSL Behring and Takeda. Iris Medina, Vanesa Pussetto, Gabriel Fueyo, Florencia Baillieau, Marcela García, Gustavo Vijoditz, Marcela Chinigo, Andrea Mariño, Patricia Ronco, Alejandra Schmid, Claudio Cambiasso, Daiana Espantoso, Miguel Galicchio, Adrián Kahn and Cora Onetti have no conflicts of interests to disclose. Acknowledgments We thank Carolina Cabilla and Fernando Gambarte, who contributed with data from their assisted patients. Footnotes Full list of author information is available at the end of the article. Supplementary data to this article can be found online at https://doi.org/10.1016/j.waojou.2026.101400. Supplementary data The following are the supplementary data to this article: Multimedia component 1 Multimedia component 2 Multimedia component 3 References Associated Data Supplementary Materials Multimedia component 1 Multimedia component 2 Multimedia component 3